Portal de Periódicos da CAPES

Case Report: Long-term metabolic response of metastatic uveal melanoma to pembrolizumab on FDG-PET/CT despite a serial pseudoprogressions phenomenon

2023; Frontiers Media; Volume: 14; Linguagem: Inglês

10.3389/fimmu.2023.1243208

1664-3224

Karim Amrane, Coline Le Meur, Philippe Thuillier, Jacques Dzuko Kamga, Pierre Alemany, Frederic Chauvelot, Clémence Niel, Alex Bellange, Ronan Abgral,

Immunotherapy and Immune Responses

Uveal melanoma (UV) is a rare and aggressive melanoma with poor 1-year survival. up to 50% of UV patients develop metastases, mainly to the liver. Here, the authors present a 2-deoxy-2-[